Lilly finalizes Zyprexa settlement with insurers; Now buying, Gruenenthal eyes Brazilian deals;

 @FiercePharma: Our take on the Novartis job cuts: One thing's sure, no reps will strike in protest ($NVS). Article | Follow @FiercePharma

> Eli Lilly ($LLY) won court approval of a $4.5 million settlement with 6 payers that claimed that the company's Zyprexa marketing caused them to overpay for the drug. Article

> Germany's Gruenenthal has earmarked $1 billion for acquisitions to expand in Latin America, and it's already shopping for deals in Brazil, CEO Harald Stock said. Story

> Perrigo plans to add 45 new store-brand, over-the-counter drugs to its stable in 2012, augmenting sales by $190 million, CEO Joseph Papa told Bloomberg. More

> Shire ($SHPGY) inked a deal with generics maker Prasco Laboratories on an authorized copy of its Carbatrol anti-seizure and nerve pain medicine. News

> CVS Caremark ($CVS) agreed to pay $5 million to settle claims that it misrepresented Medicare drug prices, closing a two-year Federal Trade Commission probe. Story

> Canada-based drug delivery specialist Kedem Pharmaceuticals ($KDMP) moved its headquarters to Mesa, AZ, and plans a new R&D lab in Scottsdale. Article

> New Jersey Gov. Chris Christie has until Tuesday to decide whether to sign or veto a repeal of the so-called "Botox Tax," the first state levy on cosmetic procedures in the U.S. News

> India's Ind-Swift has signed on to market Roche's ($RHHBY) heart-attack detection kits in India in a deal that could lead to more marketing collaborations with the Swiss company. Report

> Sri Lanka's PC Pharma is planning a stock listing to help fund acquisitions and a new manufacturing plant. More

Biotech News

@FierceBiotech: Will 2012 see a big spike in biotech buyouts? Short answer: "You can never have enough pipeline." More | Follow @FierceBiotech

@JohnCFierce: Will biotech buyouts be the focus in Europe, following end of the megadeal and a round of stock buybacks? Likely. Story | Follow @JohnCFierce

@RyanMFierce: Onyx Pharma's Matt Fust didn't say the company's for sale, but that it'd be an attractive takeover target. That sounds like selling to me. | Follow @RyanMFierce

@FierceMedDev: Device company Launch Medical investing $4.8 million in Bartlett expansion-- via @MBJMemphis. Article | Follow @FierceMedDev

> PhRMA touts pediatric pipeline as it recruits lawmakers on legislation. Story

> Onyx Pharma CFO plugs cancer pipeline amid rumored sales process. Article

And Finally... Can't break a bad habit? Blame dopamine neurons in the brain's basal ganglia, researchers say. Release